Who Paid My Doc
Rocio Delgado Diaz
Neuromuscular Medicine Gurabo, PR Medical Doctor
NPI 1487186524 CMS profile 11307395
10 Carr 189, Gurabo, PR 00778
General payments
$101
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Rocio Delgado Diaz of Gurabo, PR is reported in the CMS Open Payments database as having received $101 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $24 | 1 | |
| 2022 | General | $57 | 3 | |
| 2021 | General | $20 | 1 |
Beside peers
- Rocio Delgado Diaz
- Neuromuscular Medicine median
- Middle half of Neuromuscular Medicine
- National median
In program year 2025, general payments to Rocio Delgado Diaz were reported at $0. Among 29 Neuromuscular Medicine profiles paid that year, the median was $140 and the middle half received between $45 and $721.
Show as a table
| Year | Rocio Delgado Diaz | Neuromuscular Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $106 | $32–$174 | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $20 | $142 | $72–$2,438 | $132 |
| 2022 | $57 | $146 | $37–$459 | $149 |
| 2023 | $24 | $125 | $25–$296 | $160 |
| 2024 | $0 | $182 | $50–$398 | $164 |
| 2025 | $0 | $140 | $45–$721 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
467
Drug cost
$5,583
Branded share of claims
6.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Diclofenac Potassium | Generic | 60 | $1,760 | |
| Orphenadrine Citrate Er Orphenadrine Citrate | Brand | 32 | $962 | |
| Gabapentin | Generic | 158 | $935 | |
| Methylprednisolone | Generic | 78 | $664 | |
| Celecoxib | Generic | 34 | $355 | |
| Diclofenac Sodium | Generic | 29 | $293 | |
| Triamcinolone Acetonide | Generic | 23 | $225 | |
| Nabumetone | Generic | 14 | $173 | |
| Baclofen | Generic | 15 | $98 | |
| Pantoprazole Sodium | Generic | 11 | $69 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neuromuscular Medicine in Puerto Rico
Related records
Neuromuscular Medicine in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Neuromuscular Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.